Eric FURFINE,Daniel Dix,Kenneth S. Graham,Kelly Frye
申请号:
US13329770
公开号:
US20120087929A1
申请日:
2011.12.19
申请国别(地区):
US
年份:
2012
代理人:
摘要:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4.